✦ LIBER ✦

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors : A Children's Oncology Group Study

✍ Scribed by Lisa M. McGregor; Sheri L. Spunt; Wayne L. Furman; Clinton F. Stewart; Paula Schaiquevich; Mark D. Krailo; RoseAnne Speights; Percy Ivy; Peter C. Adamson; Susan M. Blaney

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 533 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24175

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 study of an oxaliplatin and etop

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

✍ Lisa M. McGregor; Sheri L. Spunt; Victor M. Santana; Clinton F. Stewart; Deborah 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 1 views

Phase I trial of trimetrexate in pediatr

Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study

✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

5-fluorouracil and cis-platinum in the t

5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I — II study

✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

Phase I study of a 120-hour continuous i

Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study

✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

Phase I study of fotemustine in pediatri

Phase I study of fotemustine in pediatric patients with refractory brain tumors

✍ Darren R. Hargrave; Eric Bouffet; Janet Gammon; Nauman Tariq; Ron M. Grant; Sylv 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. ## METHODS Patients younger than 21 with recurrent/res

Phase II investigation of docetaxel in p

Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors : A report from the Children's Oncology Group

✍ Ted Zwerdling; Mark Krailo; Philip Monteleone; Rebecca Byrd; Judith Sato; Rose D 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patie